The abstract will be made available on the publications section of the Capricor website.
Capricor Therapeutics’ plan to seek early approval for a stem cell therapy for patients with Duchenne muscular dystrophy is ...
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Hosted on MSN2d
Here's Why Momentum in Capricor (CAPR) Should Keep goingWhen it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Capricor Therapeutics shares are trading lower by 6.05% during Thursday's session. The company earlier commenced its public offering of common stock. Capricor Therapeutics Inc CAPR shares are ...
Shares of Capricor Therapeutics fell more than 10% in premarket trading Thursday after the biotechnology company said it is raising about $75 million in a public stock offering. The San Diego ...
Capricor Therapeutics has released more positive three-year safety and efficacy data from the Phase II HOPE-2 open-label extension (OLE) trial for its Duchenne muscular dystrophy (DMD) cell ...
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback